Intermittent Docetaxel Non-Inferior to Continuous Therapy in CRPC

Article

An intermittent docetaxel regimen was non-inferior to continuous docetaxel therapy in patients with metastatic castration-resistant prostate cancer.

An intermittent docetaxel regimen was non-inferior to continuous docetaxel therapy in patients with metastatic castration-resistant prostate cancer, according to results of a phase III trial presented at the 2016 American Society of Clinical Oncology (ASCO) Annual Meeting, held June 3–7 in Chicago (abstract 5005).

The PRINCE study compared a standard docetaxel regimen with a regimen in which the therapy is paused. “The rationale of intermittent therapy and the benefit this might hold for the patient is clearly the treatment holiday,” said Hannes Cash, MD, of Charité University Medicine Berlin in Germany, who presented the study. “With this, [there is] reduced docetaxel exposure for the patient, reduced cumulative toxicities, and possibly delayed resistance to taxanes.” He noted that the study began in 2005, when there was a need to improve docetaxel therapy and some of the newer agents were not yet available.

A total of 187 patients (156 evaluable) were randomized to receive standard continuous docetaxel treatment vs an intermittent regimen involving 12 weeks of treatment followed by a pause until disease progression, when docetaxel was started again. Progression was defined as either serum prostate-specific antigen (PSA) > 4 ng/mL with a 50% increase over baseline level, or radiological or symptomatic progression.

The 1-year survival rate in the continuous therapy group was 75%, compared with 78% in the intermittent group; this met the non-inferiority criteria for the study. As expected, the intermittent patients received a lower cumulative dose of docetaxel (368.16 mg/m2) compared with the continuous patients (444.2 mg/m2), but that difference was not statistically significant (P = .84).

The median overall survival was 18.3 months with continuous docetaxel and 19.3 months with intermittent treatment, for a hazard ratio of 1.14 (95% CI, 0.75–1.72; P = .535); a post-hoc analysis determined that this did not meet the non-inferiority criteria. Differences between the two groups with regard to progression-free survival and time to treatment failure were not significant.

“The lower cumulative dose did not translate into a lower rate of adverse effects,” Cash said. There were no differences between groups with regard to grade 3 or 4 anemia or neutropenia, fatigue, and other events. Cash noted that the study did not end up recruiting its full planned cohort, and thus it remains “speculative” what the outcomes may have been with more patients. He concluded that based on this data, though, this regimen may be offered to metastatic prostate cancer patients.

The discussant for the session, Derek Raghavan, MD, PhD, of the Levine Cancer Institute in Charlotte, North Carolina, said that he thinks “it is reasonable to offer patients a chemo holiday.” He noted that this can reduce costs of therapy without a significant detriment to patients.

Recent Videos
The National ICE-T Conference may inspire future collaboration between community and academic oncologists in the management of different cancers.
One of the largest obstacles to tackle in the kidney cancer landscape will be translating the research on rare kidney cancer subtypes into clinical trials.
Long-term toxicities like infections and secondary primary malignancies remain a concern when sequencing novel agents for those with multiple myeloma.
Zanzalitinib exhibited favorable data when evaluated alone or in combination with anti-PD-1 immune checkpoint inhibition in phase 1 RCC trials.
The investigational agent exhibited superior efficacy vs pembrolizumab in patients with lung cancer, suggesting potential efficacy in kidney cancer.
Management of adverse effects and access to cellular therapies among community oncologists represented key points of discussion in multiple myeloma.
“As a community, if we’re looking to help enroll and advocate for patients with rare [kidney cancers], we need to be aware of what is out there,” said A. Ari Hakimi, MD.
Treatment with the dual inhibitor displayed a short half-life and a manageable toxicity profile in patients with clear cell renal cell carcinoma.
The annual Kidney Cancer Research Summit was born from congressional funding for kidney cancer research, according to KidneyCAN president Bryan Lewis.
Combining renal vaccines with immune therapy may better target tumor cells while limiting harm to healthy tissue, according to David A. Braun, MD, PhD.
Related Content